The JMP family of products provide many capabilities that help you to leverage data better, and this seminar focuses on two distinct but related areas of application.
Andrew Lawton, CEO of Risk Based Approach Ltd, will examine and interpret forthcoming regulations and guidance changes and the use of big data and analytics.
Geoffrey Mann, JMP Product Manager at SAS, will discuss how to modernize your on-site clinical trial monitoring by using the latest methods in risk-based monitoring, central statistical monitoring and clinical oversight monitoring.
Ron Kenett, Chairman of the KPA Group, insights through analytics, will provide an overview of the data-driven aspects of Quality by Design (QbD) and the associated FDA guidance.
